CSL – Credit Suisse rates the stock as Outperform

By Broker News | More Articles by Broker News

Following on from the release of the latest industry statistics in the USA, Credit Suisse analysts point out US IG volume growth appears to be running ahead still of the upper level that most plasma participants have indicated as reflecting underlying demand.

The underlying suggestion here is the industry as a whole is experiencing strong underlying demand. No changes made. Target price remains $230. Outperform.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $230.00.Current Price is $194.85. Difference: $35.15 – (brackets indicate current price is over target). If CSL meets the Credit Suisse target it will return approximately 15% (excluding dividends, fees, and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →